Back
Filter by:
  • Trial Status
  • Trial Phase
  • Age
  • Sex
  • Location

    location

    Clear All

About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

339,504 studies
in
214 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 05/30/2020.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 05/30/2020.
Displaying: 77 trials in your specialties ()
View trials across your selected specialties

Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction

  • Status
    Active, not recruiting
  • Phase
    Phase 1
  • Condition
    Glioma, Hematopoietic and Lymphoid Cell Neoplasm, Lymphoma, Metas...
View Full Trial
INTERVENTION

Other: Pharmacological Study, Drug: Romidepsin

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

City of Hope Comprehensive Cancer Center, Duarte, California, United States

Brief Summary

This phase I trial studies the side effects and best dose of romidepsin in treating patients with lymphoma, chronic lymphocytic leukemia, or solid tumors with liver dysfunction. Romidepsin may stop the growth of cancer cells by entering the cancer cells and by blocking the activity of proteins that are important for the cancer's growth and survival.

Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies

  • Status
    Recruiting
  • Phase
    Phase 1 Phase 2
  • Condition
    Lymphoid Malignancies, Multiple Myeloma, Lymphoma, Hodgkin Lympho...
View Full Trial
INTERVENTION

Drug: Pralatrexate, Drug: Romidepsin

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Brief Summary

This is a study to test how safe the combination of the drugs Romidepsin and Pralatrexate are in patients with lymphoid malignancies and to determine the dose of the combination of drugs that is safest. If the combination is determined to be safe, the study will continue accrual patients with peripheral T-Cell lymphoma (PTCL).

A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma

  • Status
    Recruiting
  • Phase
    Phase 2
  • Condition
    Previously Treated Unresectable or Metastatic Cholangiocarcinoma ...
View Full Trial
INTERVENTION

Drug: Entinostat, Drug: Nivolumab, Drug: Entinostat, Drug: Nivolumab

Eligibility
  • Ages: 18 to 100 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States

Brief Summary

The proposed study is an open-label, two-arm study of entinostat plus nivolumab in patients with unresectable or metastatic CCA or PDAC.

Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas

  • Status
    Active, not recruiting
  • Phase
    Phase 1
  • Condition
    Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Hodgki...
View Full Trial
INTERVENTION

Drug: Romidepsin, Drug: Gemcitabine, Drug: Oxaliplatin, Drug: Dexamethasone, Drug: Pegfilgrastim

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

University of Chicago, Chicago, Illinois, United States

Brief Summary

The purpose of this research study is to find the maximum tolerated dose of a drug called romidepsin when given with a treatment regimen called GemOxD. GemOxD is a routine treatment for certain types of lymphoma, and involves the administration of three drugs: gemcitabine, oxaliplatin, and dexamethasone. In addition to finding the maximum tolerated dose of romidepsin, the investigators want to look at the side effects of these drugs when given together, as well as how the lymphoma responds to this treatment.

Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma

  • Status
    Active, not recruiting
  • Phase
    Phase 1
  • Condition
    Lymphoma, T-Cell Lymphoma, Cutaneous Lymphoma
View Full Trial
INTERVENTION

Drug: Istodax, Drug: Doxil

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

University of California, San Francisco, San Francisco, California, United States

Brief Summary

This a multi-center, single arm, open-label, Phase I dose-finding and preliminary efficacy study of the combination of the histone deacetylase inhibitor romidepsin (Istodax®) in combination with doxorubicin HCl liposomal (Doxil®) for adult patients with relapsed or refractory cutaneous T-cell lymphoma after at least 2 lines of skin-directed therapy or one prior line of systemic therapy. Patients will be treated with Doxil 20mg/m2 on day 1 and romidepsin 8-14mg/m2 on days 1, 8 and 15, every 28 days, until 2 cycles beyond the best response, 8 cycles, disease progression or intolerability whichever comes first. Importantly, doxil is administered prior to romidepsin on day1 of each cycle. Patients will be followed until disease progression or death whichever comes first.

Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas

  • Status
    Recruiting
  • Phase
    Phase 1 Phase 2
  • Condition
    Peripheral T-cell Lymphomas (PTCL), PTCL-NOS, Angioimmunoblastic ...
View Full Trial
INTERVENTION

Drug: Ro-CHOEP-21 (PHASE I), Drug: Ro-CHOEP-21 (PHASE II)

Eligibility
  • Ages: 18 to 65 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Ospedale SS. Antonio e Biagio e Cesare Arrigo, Alessandria, AL, Italy

Brief Summary

This is a multicenter study that includes two phases: 1. A phase I study to define the maximum tolerated dose (MTD) of Romidepsin in addition to CHOEP-21 and to test the safety and feasibility of CHOEP-21 in combination with dose escalation of Romidepsin (8, 10, 12, 14 mg). The dose level defined as MTD of Romidepsin will be used for the subsequent phase II study. 2. A phase II study to evaluate the efficacy (response rate, progression free survival and overall survival) and safety of Ro-CHOEP-21 incorporated into a treatment strategy including SCT.

A Study of ABT-199 (Venetoclax) for Cutaneous T Cell Lymphoma (CTCL)

  • Status
    Recruiting
  • Phase
    Phase 1
  • Condition
    CTCL
View Full Trial
INTERVENTION

Drug: ABT-199 (venetoclax)

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Yale New Haven Hospital / Smilow Cancer Center, New Haven, Connecticut, United States

Brief Summary

The objective of this study are to evaluate the safety and tolerability of ABT-199 (venetoclax) in patients with advanced Cutaneous T cell lymphoma (CTCL). A secondary objective is to explore clinical response to ABT-199 (venetoclax) in patients with advanced CTCL.

Study of Pembrolizumab (MK-3475) in Combination With Romidepsin

  • Status
    Recruiting
  • Phase
    Phase 1 Phase 2
  • Condition
    Recurrent Mycosis Fungoides, Recurrent Primary Cutaneous T-Cell N...
View Full Trial
INTERVENTION

Biological: Pembrolizumab, Drug: Romidepsin

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

M D Anderson Cancer Center, Houston, Texas, United States

Brief Summary

This phase I/II trial studies the side effects of pembrolizumab and romidepsin and to see how well they work in treating participants with peripheral T-cell lymphoma that has come back or that does not respond to treatment. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Romidepsin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and romidepsin may work better than pembrolizumab alone in treating participants with recurrent or refractory peripheral T-cell lymphoma.

A Safety and Efficacy Study of Pracinostat and Azacitidine in Patients With High Risk Myelodysplastic Syndromes

  • Status
    Active, not recruiting
  • Phase
    Phase 2
  • Condition
    Myelodysplastic Syndromes
View Full Trial
INTERVENTION

Drug: Pracinostat, Drug: Azacitidine

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

City of Hope, Duarte, California, United States

Brief Summary

This is a Phase 2, two-stage study of the safety and efficacy of pracinostat in combination with azacitidine in patients with IPSS-R high and very high risk MDS who are previously untreated with HMAs. Enrollment in this study will be limited to high/very high risk MDS because this group represents the highest unmet need, with median survival of less than 18 months. Stage 1a will be conducted as an open-label single arm in up to 40 subjects to assess if this regimen with a lower pracinostat dose results in a discontinuation rate that meets a predefined threshold and in efficacy that justifies expansion of enrollment into Stage 1b. A discontinuation rate of approximately ≤10% in Stage 1a, a rate comparable to that observed with azacitidine alone in study MEI-003, supports expansion into Stage 1b. Stage 1b will be conducted as expansion of stage 1a. Approximately 20 additional subjects will be enrolled. Study drugs should be continued until disease progression or intolerable toxicity. It is important to note that the median time to achieving a response with azacitidine alone is 4 to 5 months. Furthermore, the median time to achieving a CR in study MEI-003 was 4 cycles. Therefore, early (<6 months) discontinuation of trial therapy for 'no response' should be avoided. The Medical Monitor should be contacted prior to discontinuing a subject from the study to discuss the rationale for discontinuation.

Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma

  • Status
    Active, not recruiting
  • Phase
    Phase 2
  • Condition
    Metastatic Myxoid Liposarcoma, Metastatic Round Cell Liposarcoma,...
View Full Trial
INTERVENTION

Biological: Interferon Gamma-1b, Other: Laboratory Biomarker Analysis, Biological: Pembrolizumab

Eligibility
  • Ages: 12 Years and older (Child, Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Stanford Cancer Institute Palo Alto, Palo Alto, California, United States

Brief Summary

This phase II trial studies how well pembrolizumab and interferon gamma-1b work in treating patients with stage IB-IVB mycosis fungoides and Sezary syndrome that has come back (relapsed) or has not responded to previous treatment (refractory). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Interferon gamma-1b may boost the immune system activity. Giving pembrolizumab and interferon gamma-1b together may work better in treating patients with stage IB-IVB mycosis fungoides and Sezary syndrome.